J Rheumatol 2017 Mar 15. Epub 2017 Mar 15.
From Arthritis Research Canada, Richmond; Division of Rheumatology, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; Department of Rheumatology, Division of Rheumatology, Allergy and Immunology, Harvard Medical School, Boston, Massachusetts, USA. Funded by the Canadian Arthritis Network, The Arthritis Society of Canada, the British Columbia Lupus Society (grant 10-SRP-IJD-01), and the Canadian Institutes for Health Research (grants MOP-125960 and THC-135235). J.A. Aviña-Zubieta, MD, PhD, Associate Professor of Medicine, Division of Rheumatology, Department of Medicine, University of British Columbia, and Research Scientist, Arthritis Research Canada; M. Jansz, MD, Internal Medicine Resident, Department of Medicine, Faculty of Medicine, University of British Columbia; E.C. Sayre, PhD, Statistician, Arthritis Research Canada; H.K. Choi, MD, DrPH, Professor of Medicine, Department of Rheumatology, Division of Rheumatology, Allergy and Immunology, Harvard Medical School, and Research Scientist, Arthritis Research Canada. Address correspondence to Dr. J.A. Aviña-Zubieta, 5591 No. 3 Road, Richmond, British Columbia V6X 2C7, Canada. E-mail: Accepted for publication February 10, 2017.
: To estimate the future risk and time trends of venous thromboembolism (VTE) in individuals with newly diagnosed primary Sjögren syndrome (pSS) in the general population.Methods
: Using a population database that includes all residents of British Columbia, Canada, we created a study cohort of all patients with incident SS and up to 10 controls from the general population matched for age, sex, and entry time. We compared incidence rates (IR) of pulmonary embolism (PE), deep vein thrombosis (DVT), and VTE between the 2 groups according to SS disease duration. Read More